Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMT4FI5)

Drug Name

SAR-566658 Drug Info

Synonyms

CA6-targeted DM4 immunotoxin (cancer), sanofi-aventis; DM4-conjugated DS6 MAb (cancer), sanofi-aventis; DM4-conjugated anti-Muc1 monoclonal antibody (cancer), sanofi-aventis

Indication

Disease Entry	ICD 11	Status	REF
Triple negative breast cancer	2C60-2C65	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

Cross-matching ID

TTD Drug ID: DMT4FI5

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mucin-1 (MUC1)	TTBHFYQ	MUC1_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Mucin-1 (MUC1)	DTT	MUC1	3.485	8.525	9.106	5.714

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Triple negative breast cancer

ICD Disease Classification

2C60-2C65

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Mucin-1 (MUC1)	DTT	MUC1	4.59E-01	-0.07	-0.41

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01156870) First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor. U.S. National Institutes of Health.
3	Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology.Molecular Cancer Therapeutics. 11/2011; 10(Supplement 1):A73-A73.